Biotech · Private company · Saint Louis, MO, US
Vaxnewmo, LLC
Track this companyFree. Adds Vaxnewmo, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards7
- A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infectionsFiscal year 2026 · $1MNIH RePORTER 5R42AI165116-05 · fetched Nov 12, 2026
- A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infectionsFiscal year 2026 · $999KNIH RePORTER 5R44AI167078-04 · fetched Nov 12, 2026
- A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infectionsFiscal year 2025 · $1MNIH RePORTER 2R44AI167078-03A1 · fetched Nov 12, 2026
- A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infectionsFiscal year 2025 · $999.7KNIH RePORTER 5R42AI165116-04 · fetched Nov 12, 2026
- Development of a Group B Streptococcus bioconjugate vaccineFiscal year 2025 · $995.7KNIH RePORTER 5R44AI142928-05 · fetched Nov 12, 2026
- A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infectionsFiscal year 2024 · $994.2KNIH RePORTER 4R42AI165116-03 · fetched Nov 12, 2026
- Development of a Group B Streptococcus bioconjugate vaccineFiscal year 2024 · $995.7KNIH RePORTER 5R44AI142928-04 · fetched Nov 12, 2026